ADCs in Breast Cancer

CE / CME

APPlexus Oncology Spring: Clinic-Ready Insights on Emerging Data for Current Antibody–Drug Conjugates in Breast Cancer

Nurse Practitioners/Nurses: 1.00 Nursing contact hours, includes 1.00 hour of pharmacotherapy credit

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Released: April 10, 2025

Expiration: October 09, 2025

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

Which of the following patients would be eligible for sacituzumab govitecan therapy?

2.

Case Discussion 6



  • Jane is a 48-yr-old woman with a history of metastatic TNBC to lung and thoracic lymph nodes

  • Her cancer recently progressed on first-line pembrolizumab, gemcitabine, and carboplatin; her physician recommends second-line sacituzumab govitecan per ASCENT trial

  • You educate Jane about the risks of neutropenia and diarrhea associated with sacituzumab govitecan and she tolerates the first 2 cycles without significant events

  • While she is receiving her infusion on cycle 3 Day 1, she reports abdominal cramping and diarrhea

What is the next most appropriate step for Jane’s abdominal cramping and diarrhea during sacituzumab govitecan administration?

3.

When educating a patient who is about to start therapy with datopotamab deruxtecan, which of the following adverse events should you monitor/assess for?